The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

Prashant Tibrewal, Milanduth K. Kanigere, Jeffrey C.L. Looi, Stephen Allison, Tarun Bastiampillai

Research output: Contribution to journalComment/debate

Abstract

Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006). In a recent commentary, we suggested that the benefits of benzodiazepines for treatment-refractory anxiety disorders have been underestimated and their risks overestimated (Tibrewal et al., 2021a). Carefully prescribed in discussion with patients, benzodiazepines might be a safer option than some alternative agents, such as quetiapine, for long-term treatment.

Lugg’s (2022) response to our commentary (Tibrewal et al., 2021a) questions the strength of the evidence for the long-term use of benzodiazepines in anxiety disorders...
Original languageEnglish
Pages (from-to)723-724
Number of pages2
JournalAustralian and New Zealand Journal of Psychiatry
Volume56
Issue number6
Early online date18 Mar 2022
DOIs
Publication statusPublished - Jun 2022

Keywords

  • Anxiety disorders
  • Drug effects
  • Benzodiazepines
  • Long-term treatment

Fingerprint

Dive into the research topics of 'The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders'. Together they form a unique fingerprint.

Cite this